相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Immunology
Marisa Holubar et al.
Summary: This study found that commonly used doses of favipiravir did not show significant effectiveness in treating uncomplicated COVID-19 in outpatient settings. Further research is needed to determine if higher doses of favipiravir are effective and safe for patients with COVID-19.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Alessia Lai et al.
Summary: Residents of long-term care facilities have been severely affected by the COVID-19 pandemic. This study assessed the quantity and durability of antibody responses to the BNT162b2 vaccine. The results showed that antibody levels decreased over time, but positive nucleocapsid serology was associated with a reduced risk of suboptimal response. Furthermore, diabetes was associated with an increased risk of impaired immune response.
Article
Biochemistry & Molecular Biology
Jeffrey V. Lazarus et al.
Summary: Survey data from 19 countries reveals varying attitudes towards acceptance of a COVID-19 vaccine, with trust in government being linked to vaccine confidence.
Article
Virology
Hany M. Dabbous et al.
Summary: Favipiravir shows promising efficacy in the treatment of COVID-19, reducing hospital stay and the need for mechanical ventilation.
ARCHIVES OF VIROLOGY
(2021)
Review
Infectious Diseases
Shashank Joshi et al.
Summary: Favipiravir has shown promising results in clinical studies worldwide, demonstrating potential efficacy against COVID-19, and is being included in treatment protocols by multiple countries.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Carolina Lucas et al.
Summary: This study found that individuals previously infected with the virus had higher antibody titres post-vaccination compared to those who were uninfected, but both groups reached comparable levels of neutralization responses to the ancestral strain after the second vaccine dose. Comprehensive analysis of 16 locally circulating SARS-CoV-2 variants revealed varying degrees of reduction in neutralization capacity associated with specific mutations in the spike gene, suggesting vaccine boosters as a relevant future strategy to counteract the impact of emerging variants on antibody neutralizing activity.
Article
Biochemistry & Molecular Biology
Rita E. Chen et al.
Summary: The study analyzed antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants, showing significantly reduced neutralizing activity against the B.1.351 variant first identified in South Africa. Antibodies targeting the receptor-binding domain and N-terminal domain, monoclonal antibodies, convalescent sera, and mRNA vaccine-induced immune sera exhibited decreased inhibitory activity against viruses with an E484K spike mutation, suggesting a need for updated monoclonal antibodies or vaccine adjustments to prevent loss of protection against emerging variants.
Article
Microbiology
Hitoshi Kawasuji et al.
Summary: The study shows that there is a decline in antibody levels and neutralizing activity against variant viruses induced by the BNT162b2 vaccine with increasing age, while the neutralizing activity against the wild-type virus remains stable. This suggests a potential weakness of mRNA vaccines in providing protection against viral variants, particularly in older age groups.
MICROBIOLOGY SPECTRUM
(2021)
Review
Infectious Diseases
Toshie Manabe et al.
Summary: The study suggests that favipiravir shows promising efficacy in treating patients with COVID-19, inducing viral clearance within 7 days and contributing to clinical improvement within 14 days. The drug is especially effective for patients with mild-to-moderate illness. However, additional well-designed studies are needed to determine the optimal dosage and duration of treatment.
BMC INFECTIOUS DISEASES
(2021)
Review
Genetics & Heredity
Kaiming Tao et al.
Summary: The emergence of multiple SARS-CoV-2 variants has significant impacts on the epidemiological and clinical aspects of the COVID-19 pandemic, including increased virus transmission rates, heightened risk of reinfection, and reduced effectiveness of neutralizing antibodies and vaccines. These variants have introduced new challenges to COVID-19 research, necessitating additional avenues of laboratory, epidemiological, and clinical studies.
NATURE REVIEWS GENETICS
(2021)
Article
Pharmacology & Pharmacy
Chang Chen et al.
Summary: This study compared the efficacy and safety of favipiravir and umifenovir (Arbidol) in treating COVID-19 patients. Although favipiravir showed a shorter duration for relief of fever and cough, it did not significantly improve the clinical recovery rate at day 7 compared to Arbidol. The adverse effects associated with favipiravir were mild and manageable.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Monika Strengert et al.
Summary: Patients on maintenance haemodialysis show detectable but variable cellular and humoral immune responses to SARS-CoV-2 and variants of concern after receiving the BNT162b2 vaccine. While encouraging, the diminished virus neutralization and interferon gamma responses in the face of emerging variants may indicate a need for re-vaccination using modified vaccines in this at-risk population.
Letter
Cell Biology
Manli Wang et al.
Article
Pharmacology & Pharmacy
Ka-Tim Choy et al.
ANTIVIRAL RESEARCH
(2020)
Article
Microbiology
Yohei Doi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2020)
Article
Respiratory System
Kota Murohashi et al.
RESPIRATORY INVESTIGATION
(2020)
Letter
Critical Care Medicine
Hitoshi Yamamura et al.
Review
Multidisciplinary Sciences
Yousuke Furuta et al.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
(2017)
